Biologics Manufacturing Korea 2024 unites industry pioneers, thought leaders, and innovators to delve into the latest trends, challenges, and breakthroughs in biopharmaceutical manufacturing. From August 13 to 15, 2024, BMK serves as a dynamic platform for networking, knowledge exchange, and collaboration...
27 January 2023 | News Share FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit of KRW 983.6 billion At the 2023 J.P. Morgan Healthcare Conference in January, Samsung Biologics, a fully integrated CDMO offering state-of-the-art contract ...
Incheon, S. Korea, November 28, 2023 – Samsung Biologics (KRX: 207940.KS), a global contract and development and manufacturing organization (CDMO), today hosted its inaugural Suppliers ESG Day, both at its Songdo headquarters and online, to share envi
Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply...
A record of $4.2 billion was funneled into influencing U.S. federal lawmakers in 2023, and the pharmaceutical and health products industries were the leading contributors, industry data showed.On Tuesday, the Korea Biotechnology Industry Organization (Ko
Lotte Biologics, attending for the second consecutive year, presented its ambitious plans for a new bio plant in Incheon Songdo. CEO Richard Lee emphasized the concept of "design" in bridging market demand with supply capabilities in the contract development and manufacturing organization (CDMO) secto...
Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million . Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as
These include the cutting-edge manufacturing technologies of its Syracuse site, robust process development services, stringent quality systems, and ambitious plans to inaugurate a state-of-the-art Mega Plant in South Korea. LOTTE BIOLOGICS has prepared designated meeting...
and enhance the delivery of high-concentration biologic products. BRL's technology exhibits versatility, applying various Monoclonal Antibodies and fusion proteins. Successful outcomes from this collaboration may lead to integrating these programs into Catalent's comprehensive formulation and manufacturing servic...
Samsung Biologics America is our U.S. subsidiary committed to providing trusted services in close proximity to our clients and industry partners. The San Francisco R&D Center is our first U.S. location, which supports our CDO services.